Literature DB >> 19261011

Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.

Kelley A Vidulich1, Rakhshandra Talpur, Roland L Bassett, Madeleine Duvic.   

Abstract

BACKGROUND: The most common cutaneous T-cell lymphomas (CTCLs) are mycosis fungoides and Sézary syndrome. AIM: To determine whether blood stage and other prognostic variables affect overall survival (OS) in CTCL.
METHODS: We studied retrospectively 1197 CTCL patients seen at the M.D. Anderson Cancer Center since 1987.
RESULTS: We identified 124 (10.3%) patients with erythrodermic CTCL (E-CTCL), 63% of whom had positive gene rearrangements in skin and 19 of whom had no evidence of hematologic involvement. The median age at diagnosis was 63 years (range, 26-90 years); the male to female ratio was 1.3 : 1. OS curves were estimated by the Kaplan-Meier method and compared using log-rank tests. The median OS in all 124 E-CTCL patients was 5.1 years (range, 0.4-18.6 years) regardless of the cause of death or blood involvement. Patients were stratified by the H0-H4 staging system with manual or flow cytometric determination of Sézary cell counts (Russell-Jones R, Whittaker SJ. Sézary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg 2000; 19: 100-108). The median OS was 7.6 years for H0-H2 (< 1000 Sézary cells/L) (n = 23), 5.4 years for H3 (>or= 1000 to <or= 10,000 Sézary cells/L) (n = 79), and 2.4 years for H4 (>or= 10,000 Sézary cells/L) (n = 22) (P = 0.011). Treatment with systemic steroids, age, serum lactate dehydrogenase, and white blood cell count >or= 20,000 microL were significant prognostic factors, but large cell transformation, T-cell receptor gene rearrangement, tumor-node-metastasis stage, treatments, and CD4 : CD8 ratio were not. In multivariate analysis, advanced age and elevated lactate dehydrogenase were the strongest predictors of a poor prognosis.
CONCLUSIONS: Serum LDH and age were the strongest predictive factors for OS in E-CTCL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261011     DOI: 10.1111/j.1365-4632.2009.03771.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  21 in total

1.  Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Authors:  Melissa Pulitzer; Patricia L Myskowski; Steven M Horwitz; Christiane Querfeld; Brian Connolly; Janet Li; Rajmohan Murali
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.

Authors:  Enrico Scala; Damiano Abeni; Debora Pomponi; Maria Grazia Narducci; Giuseppe Alfonso Lombardo; Adriano Mari; Marina Frontani; Maria Cristina Picchio; Maria Antonietta Pilla; Elisabetta Caprini; Giandomenico Russo
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

3.  Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Philippe Thibault; Pamela Gangar; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Kevin Pehr; Victor G Prieto; Elham Rahme; Nathalie Provost; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

4.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

Review 5.  [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma].

Authors:  R Stranzenbach; S Theurich; M Schlaak
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 6.  Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.

Authors:  Madeleine Duvic; Mark Evans; Casey Wang
Journal:  Ther Adv Hematol       Date:  2016-03-17

Review 7.  The biomarker landscape in mycosis fungoides and Sézary syndrome.

Authors:  Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-02-02       Impact factor: 3.960

8.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

9.  Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma.

Authors:  Ivan V Litvinov; David A Jones; Denis Sasseville; Thomas S Kupper
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

10.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.